Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index.

Organic AIE Nanoradiosensitizer Potentiates X‐Ray Triggered Continuous Reactive Oxygen Species Generation for Potent Cancer Radioimmunotherapy

Open access

Abstract

Organic radiosensitizers (ORSs), with structural versatility, hold promise for sensitizing radiotherapy (RT) by interacting with X‐ray photons to generate reactive oxygen species (ROS). They often consist of low‐Z elements that have inherently low X‐ray deposition capability. However, current ORSs suffer from short circulation half‐lives and low tumor retention, contradicting their requirements for sustained ROS generation upon RT in tumor sites. Herein, a glutathione‐responsive system is prepared, loaded with aggregation‐induced emission molecules (TPEPy‐I) and Ferriprotoporphyrin IX chloride (Hemin), to act as an ORS (named THN) for X‐ray triggered sustained ROS generation for efficient antitumor immunotherapy. In detail, THN effectively deposited X‐ray photons, which interact with water molecules to generate abundant ROS under external radiation. Subsequently, THN‐mediated radiosensitization stimulated tumor cells to produce hydrogen peroxide (H 2 O 2 ) by upregulating NOX4 protein, promoting the chemodynamic process of Hemin reacting with H 2 O 2 to continuously produce hydroxyl radicals. The double‐promoting ROS generation of THN induced massive immunogenic cancer cell death and polarized M2 macrophages into the M1 phenotype for enhanced antitumor immunotherapy. Experiments revealed that THN‐sensitized RT inhibited tumor recurrence and increased memory T‐cell proportion for long‐term antitumor immunity. The developed ORS has great clinical potential as both a radiosensitizer and a post‐RT immunomodulatory agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adma.202502898

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Scheme 1 Schematic illustration of organic nano‐radiosensitizer based on AIEgens for X‐ray triggered continuous ROS generation in tumors and efficient radioimmunotherapy. a) Preparation and function of THN. b) The anti‐tumor mechanism of THN.
Scheme 1 Schematic illustration of organic nano‐radiosensitizer based on AIEgens for X‐ray triggered continuous ROS generation in tumors and efficient radioimmunotherapy. a) Preparation and function of THN. b) The anti‐tumor mechanism of THN.CC BY · PubMed Central
Figure 1 TEM image and diameter distribution of (A) TN, B) HN, and C) THN. D) Absorption spectra of TPEPy‐I in DMSO, Hemin in DMSO, THN in PBS, and BN (bare nanoparticles without drug loading in PBS). E) Stability of THN in various solutions at different times. F) HAADF‐SETM images and element mapping of THN. G) TEM image of THN after 10 mm GSH treatment for 4h. H) GSH residual rates at different times of incubation with BN or THN. I) Oxidation and J) Absorbance change at 652nm of TMB due to generated •OH by indicated treatments. i: THN in PBS, ii: THN+TMB+H2O2. K) ESR spectra showing the •OH of THN with H2O2 (25 µm).
Figure 1 TEM image and diameter distribution of (A) TN, B) HN, and C) THN. D) Absorption spectra of TPEPy‐I in DMSO, Hemin in DMSO, THN in PBS, and BN (bare nanoparticles without drug loading in PBS). E) Stability of THN in various solutions at different times. F) HAADF‐SETM images and element mapping of THN. G) TEM image of THN after 10 mm GSH treatment for 4h. H) GSH residual rates at different times of incubation with BN or THN. I) Oxidation and J) Absorbance change at 652nm of TMB due to generated •OH by indicated treatments. i: THN in PBS, ii: THN+TMB+H2O2. K) ESR spectra showing the •OH of THN with H2O2 (25 µm).CC BY · PubMed Central
Figure 2 A) Schematic illustration of energy‐dependent simulations. B) Energy deposit of THN or water under different photo energy X‐ray irradiation and C) corresponding dose enhancement ratio (DER). D) Schematic illustration of distance‐dependent simulations. E) Energy deposition and F) DER at different distances from THN or water under X‐ray irradiation. Measurement of G) hydroxyl radical, H) superoxide anion, and I) total ROS generation with fluorescence enhancement of corresponding indicator for Ce6 (in DMSO/water mixture, fw = 99%), TPEPy‐I (in DMSO/water mixture, fw = 99%) and THN upon X‐ray irradiation with different dosage. The concentration of TPEPy‐I and Ce6 is 50 µg mL−1.
Figure 2 A) Schematic illustration of energy‐dependent simulations. B) Energy deposit of THN or water under different photo energy X‐ray irradiation and C) corresponding dose enhancement ratio (DER). D) Schematic illustration of distance‐dependent simulations. E) Energy deposition and F) DER at different distances from THN or water under X‐ray irradiation. Measurement of G) hydroxyl radical, H) superoxide anion, and I) total ROS generation with fluorescence enhancement of corresponding indicator for Ce6 (in DMSO/water mixture, fw = 99%), TPEPy‐I (in DMSO/water mixture, fw = 99%) and THN upon X‐ray irradiation with different dosage. The concentration of TPEPy‐I and Ce6 is 50 µg mL−1.CC BY · PubMed Central
Figure 3 A) Confocal laser scanning microscopy (CLSM) images and B) quantitative red fluorescence intensity of 4T1 cancer cells treated with labeled THN. DAPI: blue; TPEPy‐I: red; Lyso‐Tracker Green: green. THN concentration: 10 µg mL−1. C) Production of intracellular H2O2 by RT. D) CLSM images and of •OH (green fluorescence) generated in 4T1 cells at different times after treatments. E) •OH fluorescence intensity of Figure 2D (60 min). F) Expression of γ‐H2AX (red fluorescence) and G) γ‐H2AX Foci density from 4T1 cells following treatment with different formulations. RT: 4Gy. H) The intracellular GSH content after 60 min of different treatments. I) Clonogenic survival assay of 4T1 cells treated with different formulations. J) Clonogenic survival assay of 4T1 cells treated with different formulations under a series of radiation doses at 0, 2, 4, 6, and 8 Gy. TPEPy‐I concentration: 100 µg mL−1. Data are represented as mean ± standard deviation (SD). Statistical significance was calculated via one‐way ANOVA with Tukey's test: *** p < 0.001.
Figure 3 A) Confocal laser scanning microscopy (CLSM) images and B) quantitative red fluorescence intensity of 4T1 cancer cells treated with labeled THN. DAPI: blue; TPEPy‐I: red; Lyso‐Tracker Green: green. THN concentration: 10 µg mL−1. C) Production of intracellular H2O2 by RT. D) CLSM images and of •OH (green fluorescence) generated in 4T1 cells at different times after treatments. E) •OH fluorescence intensity of Figure 2D (60 min). F) Expression of γ‐H2AX (red fluorescence) and G) γ‐H2AX Foci density from 4T1 cells following treatment with different formulations. RT: 4Gy. H) The intracellular GSH content after 60 min of different treatments. I) Clonogenic survival assay of 4T1 cells treated with different formulations. J) Clonogenic survival assay of 4T1 cells treated with different formulations under a series of radiation doses at 0, 2, 4, 6, and 8 Gy. TPEPy‐I concentration: 100 µg mL−1. Data are represented as mean ± standard deviation (SD). Statistical significance was calculated via one‐way ANOVA with Tukey's test: *** p < 0.001.CC BY · PubMed Central
Figure 4 A) CLSM images and of CRT and B) HMGB1 expression in 4T1 cells upon different treatments. C) Schematic illustration of the maturation of BMDCs in vitro. D) Quantitative analysis and E) Flow cytometry analysis and of mature BMDCs after different treatments. Data are shown as the mean ± SD (n = 3). F) The levels of TNF‐α, G) IL‐6, H) IL‐1β and I) IL‐12p70 are secreted by matured BMDCs. J) Schematic illustration of the macrophage polarization in vitro. K) Flow cytometry analysis and L) Quantitative analysis of M1 type macrophages (F4/80+CD80+) after different treatments. M) The levels of IL‐10, N) IL‐1β, and O) TGF‐β are secreted by macrophages. TPEPy‐I concentration: 100 µg mL−1. RT:4Gy. Data are shown as the mean ± SD (n = 3). Statistical significance was calculated via one‐way ANOVA with Tukey's test: ns: Non‐Significant, *** p < 0.001.
Figure 4 A) CLSM images and of CRT and B) HMGB1 expression in 4T1 cells upon different treatments. C) Schematic illustration of the maturation of BMDCs in vitro. D) Quantitative analysis and E) Flow cytometry analysis and of mature BMDCs after different treatments. Data are shown as the mean ± SD (n = 3). F) The levels of TNF‐α, G) IL‐6, H) IL‐1β and I) IL‐12p70 are secreted by matured BMDCs. J) Schematic illustration of the macrophage polarization in vitro. K) Flow cytometry analysis and L) Quantitative analysis of M1 type macrophages (F4/80+CD80+) after different treatments. M) The levels of IL‐10, N) IL‐1β, and O) TGF‐β are secreted by macrophages. TPEPy‐I concentration: 100 µg mL−1. RT:4Gy. Data are shown as the mean ± SD (n = 3). Statistical significance was calculated via one‐way ANOVA with Tukey's test: ns: Non‐Significant, *** p < 0.001.CC BY · PubMed Central
Figure 5 A) Pharmacokinetic curves of THN. B) In vivo biodistribution of THN after injections. C) Schematic diagram of therapy strategy. D) The H2O2 content in tumor tissue at different time points after RT. E) Tumor volumes were measured every 3 days across all groups. F) Tumor weights were recorded for each treatment at the end of the study. G) Survival curves after treatment. H) HE, I) TUNEL, J) ROS, and Ki‐67 staining of tumor sections after the indicated treatments. TPEPy‐I dose: 10 mg kg−1. RT dose: 4 Gy. Data are shown as the mean ± SD (n = 5). The p values were calculated via one‐way ANOVA, *** p < 0.001.
Figure 5 A) Pharmacokinetic curves of THN. B) In vivo biodistribution of THN after injections. C) Schematic diagram of therapy strategy. D) The H2O2 content in tumor tissue at different time points after RT. E) Tumor volumes were measured every 3 days across all groups. F) Tumor weights were recorded for each treatment at the end of the study. G) Survival curves after treatment. H) HE, I) TUNEL, J) ROS, and Ki‐67 staining of tumor sections after the indicated treatments. TPEPy‐I dose: 10 mg kg−1. RT dose: 4 Gy. Data are shown as the mean ± SD (n = 5). The p values were calculated via one‐way ANOVA, *** p < 0.001.CC BY · PubMed Central
Figure 6 A) Regulation of immune cells by THN plus RT. B) Flow cytometry analysis of intratumoral DC maturation and C) quantitative analysis. D) Flow cytometry analysis of CD8+ T cells in spleens and E) quantitative analysis. F) Flow cytometry analysis of intratumoral M1‐type macrophages and G) quantitative analysis of M1‐type macrophages. H) Flow cytometry analysis of intratumoral M2‐type macrophages and I) quantitative analysis of M2‐type macrophages. J) CD80 (red) and F4/80 (green) immunofluorescence images of tumor sections after first treatment. K) Fluorescence intensity profile of white line in Figure 5J. L) ELISA measurements of intratumorally secretions of (L) IL‐6, M) TGF‐β, N) IL‐10, O) TNF‐𝛼, and (P) IFN‐𝛾 (n = 5). TPEPy‐I dose: 10 mg kg−1. RT dose: 4 Gy. The data are presented as the means ± SD (n = 5). The p values were calculated via one‐way ANOVA, * p < 0.05, and *** p < 0.001.
Figure 6 A) Regulation of immune cells by THN plus RT. B) Flow cytometry analysis of intratumoral DC maturation and C) quantitative analysis. D) Flow cytometry analysis of CD8+ T cells in spleens and E) quantitative analysis. F) Flow cytometry analysis of intratumoral M1‐type macrophages and G) quantitative analysis of M1‐type macrophages. H) Flow cytometry analysis of intratumoral M2‐type macrophages and I) quantitative analysis of M2‐type macrophages. J) CD80 (red) and F4/80 (green) immunofluorescence images of tumor sections after first treatment. K) Fluorescence intensity profile of white line in Figure 5J. L) ELISA measurements of intratumorally secretions of (L) IL‐6, M) TGF‐β, N) IL‐10, O) TNF‐𝛼, and (P) IFN‐𝛾 (n = 5). TPEPy‐I dose: 10 mg kg−1. RT dose: 4 Gy. The data are presented as the means ± SD (n = 5). The p values were calculated via one‐way ANOVA, * p < 0.05, and *** p < 0.001.CC BY · PubMed Central
Figure 7 A) Schematic illustration of the studies of recurrence 4T1 model therapy. B) Evolution of the tumor volume and C) tumor weight after various treatments. D) Changes in body weight during the treatment period. E) Flow cytometry analysis and F) quantification of CD44+CD62L+ T lymphocytes in blood on the 7th day after the first treatment. G) H&E, and TUNEL staining of tumor sections after the indicated treatments. Data are shown as the mean ± SD (n = 5). Statistical significance was calculated via one‐way ANOVA with Tukey's test: *** p < 0.001.
Figure 7 A) Schematic illustration of the studies of recurrence 4T1 model therapy. B) Evolution of the tumor volume and C) tumor weight after various treatments. D) Changes in body weight during the treatment period. E) Flow cytometry analysis and F) quantification of CD44+CD62L+ T lymphocytes in blood on the 7th day after the first treatment. G) H&E, and TUNEL staining of tumor sections after the indicated treatments. Data are shown as the mean ± SD (n = 5). Statistical significance was calculated via one‐way ANOVA with Tukey's test: *** p < 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Research works printed but not linked: 1

  1. 10.1016/j.bioactmat.2022.01.003 · DOI

Cited by

See all 69

Metadata

Authors
Xu, Q., Zhang, M., Huang, Q., Gao, S., Chu, S., Li, Q., Chen, W., Zhang, X., Zhang, T., Tang, B. Z., & Ning, S.
Affiliations
  • Harbin Medical University (CN)
  • Liuzhou General Hospital (CN)
  • Zhengzhou University (CN)
  • Guangxi Medical University (CN)
  • Guangzhou Medical University Cancer Hospital (CN)
  • Chinese University of Hong Kong (HK)
Corresponding author
  • Xu, Qingyong
  • Zhang, Tianfu
  • Tang, Ben Zhong
  • Ning, Shipeng
Venue
Advanced Materials
Publisher
Wiley
Published
2025-06-19
Volume
37
Issue
35
Pages
e2502898-e2502898
ISSN
  • 0935-9648 (ISSN-L)
  • 1521-4095
OpenAlex
W4411434745
Cited by
69
References
67
Citations by year
2026: 58 · 2025: 11
FWCI
16.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Advanced Materials (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
Funders
  • National Natural Science Foundation of China (82303797, 82473348, 52303224)
  • Basic and Applied Basic Research Foundation of Guangdong Province (2024A1515010855)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
  • Physical Sciences › Materials Science › Materials Chemistry › Luminescence and Fluorescent Materials
Keywords
aggregation-induced emission, reactive oxygen species generation, ferriprotoporphyrin IX, hemin, NOX4, hydrogen peroxide, hydroxyl radicals, chemodynamic therapy, radioimmunotherapy, immunogenic cancer cell death, M2 macrophage polarization, tumor recurrence, memory T cells, antitumor immunity
MeSH terms
Animals, Glutathione, Hemin, Humans, Hydrogen Peroxide, Neoplasms, Radiation-Sensitizing Agents, X-Rays, Reactive Oxygen Species, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Organic AIE Nanoradiosensitizer Potentiates X‐Ray Triggered Continuous Reactive Oxygen Species Generation for Potent Cancer Radioimmunotherapy. https://app.cochat.ai/papers/10.1002/adma.202502898
The paper
Xu, Q., Zhang, M., Huang, Q., Gao, S., Chu, S., Li, Q., Chen, W., Zhang, X., Zhang, T., Tang, B. Z., & Ning, S. (2025). Organic AIE Nanoradiosensitizer Potentiates X‐Ray Triggered Continuous Reactive Oxygen Species Generation for Potent Cancer Radioimmunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202502898

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.